Latest & greatest articles for pravastatin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pravastatin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pravastatin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pravastatin

1. Pravastatin sodium (pravachol)

Pravastatin sodium (pravachol) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing

2020 Health Canada - drugs and medical devices

2. Pravastatin

Pravastatin Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing the Clinical Information

2020 Health Canada - drugs and medical devices

3. Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials. (Full text)

Effect of pravastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials. Pravastatin has been suggested to increase circulating adiponectin in humans. However, results of randomized controlled trials (RCTs) are inconsistent. We aimed to systematically evaluate the influence of pravastatin on circulating adiponectin in humans by performing a meta-analysis of RCTs.Studies were identified via systematic searching of PubMed, Embase, and Cochrane's Library (...) databases. A random effect model was used to pool the results. Meta-regression and subgroup analyses were applied to explore the source of heterogeneity.Eight RCTs with nine comparisons of 595 participants were included. Pravastatin treatment was associated with a significant increased level of circulating adiponectin as compared with controls (weighted mean difference [WMD] =0.63 µg/mL; 95% CI, 0.17-1.09 µg/mL; P=0.007) with moderate heterogeneity (I2=28%). These results were confirmed by meta-analysis

2020 Drug design, development and therapy PubMed abstract

4. Pravastatin (Pravachol)

Pravastatin (Pravachol) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing the Clinical

2020 Health Canada - drugs and medical devices

5. Pravastatin

Pravastatin Top results for pravastatin - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for pravastatin The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you

2018 Trip Latest and Greatest

6. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. (Abstract)

Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. We have performed a systematic search to summarize the role of statins for preventing and treating severe preeclampsia.The aim of this study was to examine whether pravastatin is a useful and safe alternative for treating preeclampsia during pregnancy.A systematic MEDLINE (PubMed) search was performed (1979 to June 2017), which was restricted to articles published in English, using the relevant key words of "statins

2018 Obstetrical & Gynecological Survey

7. Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study (Full text)

Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study We aimed to assess the long-term effects of treatment with statin therapy on all-cause mortality, cause-specific mortality, and cancer incidence from extended follow-up of the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) trial.LIPID initially compared pravastatin and placebo over 6 years in 9014 patients with previous coronary heart (...) disease. After the double-blind period, all patients were offered open-label statin therapy. Data were obtained over a further 10 years from 7721 patients, by direct contact for 2 years, by questionnaires thereafter, and from mortality and cancer registries. During extended follow-up, 85% assigned pravastatin and 84% assigned placebo took statin therapy. Patients assigned pravastatin maintained a significantly lower risk of death from coronary heart disease (relative risk [RR] 0.89; 95% confidence

2016 EvidenceUpdates PubMed abstract

8. Commentary on pravastatin and cancer: need for individual patient data meta-analyses. (Abstract)

Commentary on pravastatin and cancer: need for individual patient data meta-analyses. 20101642 2010 04 19 2013 11 21 1099-1557 19 2 2010 Feb Pharmacoepidemiology and drug safety Pharmacoepidemiol Drug Saf Commentary on pravastatin and cancer: need for individual patient data meta-analyses. 203-4; author reply 205 10.1002/pds.1910 Bonovas Stefanos S Nikolopoulos Georgios G Sitaras Nikolaos M NM eng Comment Letter England Pharmacoepidemiol Drug Saf 9208369 1053-8569 0 Anticholesteremic Agents (...) KXO2KT9N0G Pravastatin IM Pharmacoepidemiol Drug Saf. 2010 Feb;19(2):196-202 19856484 Anticholesteremic Agents adverse effects pharmacology Controlled Clinical Trials as Topic Humans Japan Meta-Analysis as Topic Middle Aged Neoplasms complications Pravastatin adverse effects pharmacology Reference Standards 2010 1 27 6 0 2010 1 27 6 0 2010 4 20 6 0 ppublish 20101642 10.1002/pds.1910

2013 Pharmacoepidemiology and drug safety

9. Pravafenix - fenofibrate / pravastatin

Pravafenix - fenofibrate / pravastatin 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report for PRAVAFENIX International nonproprietary name: fenofibrate / pravastatin Procedure No. EMEA/H/C/001243 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted Pravafenix CHMP (...) patients. The treatment is limited to patients who have not responded adequately to dietary measures and other non-pharmacological treatments (e.g. exercise, weight reduction) and to a treatment with pravastatin 40 mg monotherapy or an equivalent statin monotherapy regimen.” The legal basis for this application refers to: Article 10(b) of Directive 2001/83/EC – fixed combination application The application submitted is composed of administrative information, complete quality data, non-clinical

2011 European Medicines Agency - EPARs

10. Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy (Abstract)

Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy Patients with mixed hyperlipidemia and at high risk of coronary heart disease may not achieve recommended low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol goals on statin monotherapy. This study was designed to evaluate the efficacy and safety of a fenofibrate 160 mg/pravastatin 40 mg fixed-dose combination therapy (...) in high-risk patients not at their LDL cholesterol goal on pravastatin 40 mg. In this 12-week, multicenter, randomized, double-blind, double-dummy, parallel-group study, after a run-in on pravastatin 40 mg, 248 patients were randomly assigned to fenofibrate/pravastatin combination therapy or to pravastatin monotherapy. Combination therapy produced significantly greater complementary decreases in non-HDL cholesterol (primary end point) than pravastatin monotherapy (-14.1% vs -6.1%, p = 0.002

2010 EvidenceUpdates Controlled trial quality: uncertain

11. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance (Abstract)

Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance Currently, no consensus has been reached regarding the management of hyperlipidemia in patients who develop statin-associated myalgia (SAM). Many statin-intolerant patients use alternative lipid-lowering therapies, including red yeast rice. The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other (...) statins because of myalgia. The study was conducted in a community-based setting in Philadelphia, Pennsylvania. A total of 43 adults with dyslipidemia and a history of statin discontinuation because of myalgia were randomly assigned to red yeast rice 2,400 mg twice daily or pravastatin 20 mg twice daily for 12 weeks. All subjects were concomitantly enrolled in a 12-week therapeutic lifestyle change program. The primary outcomes included the incidence of treatment discontinuation because of myalgia

2010 EvidenceUpdates Controlled trial quality: uncertain

12. Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. (Abstract)

Pravastatin use and cancer risk: a meta-analysis of individual patient data from long-term prospective controlled trials in Japan. To assess the influence of pravastatin therapy on cancer morbidity and mortality by a meta-analysis of individual patient data (IPD) from three independent Japanese large-scale clinical trials.We conducted a meta-analysis of IPD collected from three large-scale prospective studies, the Management of Elevated Cholesterol in the Primary Prevention Group of Adult (...) Japanese (MEGA) Study, Kyushu Lipid Intervention Study (KLIS), and Hokuriku Lipid Coronary Heart Disease Study-Pravastatin Atherosclerosis Trial (Holicos-PAT), which compared cardiovascular outcomes with pravastatin therapy and non-statin therapy in Japanese patients with hypercholesterolemia over a follow-up period of >or=4 years. The incidence of cancer or cancer death in the pravastatin and non-statin therapy groups was compared by multivariate Cox proportional hazard models stratified by trial

2010 Pharmacoepidemiology and drug safety

13. [Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes]. (Abstract)

[Pravastatin and acetylsalycilic acid fixed-combination: a strategy to improve cardiovascular outcomes]. The rationale behind combined statin-acetylsalicylic acid therapy is based on the beneficial effects ofacetylsalicylic acid on thrombosis, the leading immediate cause of the majority of occlusive cardiovascular events, and those of statins on atherosclerosis, which is the main underlying cause. The clinical benefits of combined pravastatin-acetylsalicylic acid in the management of coronary (...) patients have been demonstrated by a meta-analysis of five randomized clinical trials for secondary prevention; compared with pravastatin alone, the pravastatin-acetylsalicylic acid combination reduced the risk of fatal or non fatal myocardial infarction by 26%, the risk of ischemic stroke by 31%, and the risk of cardiovascular events at 5 years by 13%. Combined pravastatin-acetylsalicylic acid therefore appears to significantly reduce the cardiovascular risk in coronary patients. Following the AHA/ACC

2009 American journal of cardiovascular drugs : drugs, devices, and other interventions

14. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (Full text)

Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Dyslipidemia is common in patients with chronic kidney disease. The role of statin therapy in the progression of kidney disease is unclear.Prospective randomized clinical trial, post hoc analyses.10,060 participants in the Antihypertensive and Lipid-Lowering (...) Treatment to Prevent Heart Attack Trial (lipid-lowering component) stratified by baseline estimated glomerular filtration rate (eGFR): less than 60, 60 to 89, and 90 or greater mL/min/1.73 m(2). Mean follow-up was 4.8 years.Randomized; pravastatin, 40 mg/d, or usual care.Total, high-density lipoprotein, and low-density lipoprotein cholesterol; end-stage renal disease (ESRD), eGFR.Through year 6, total cholesterol levels decreased in the pravastatin (-20.7%) and usual-care groups (-11.2%). No significant

2008 EvidenceUpdates Controlled trial quality: uncertain PubMed abstract

15. Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years

Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 years Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 yearsCommentary | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Primary prevention with pravastatin for 5 years continued to prevent coronary events in the next 10 yearsCommentary Article Text Treatment Primary prevention with pravastatin for 5

2008 Evidence-Based Nursing

16. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to examine the cost-effectiveness of rosuvastatin in comparison with atorvastatin, simvastatin, and pravastatin for managing lipid parameters in patients with hypercholesterolaemia. The authors

2008 NHS Economic Evaluation Database.

17. Does pravastatin promote cancer in elderly patients? A meta-analysis. (Full text)

Does pravastatin promote cancer in elderly patients? A meta-analysis. An increase in the incidence of cancer among elderly people assigned to pravastatin therapy has been reported in a randomized controlled trial; however, this finding has been attributed to chance. Our aim was to assess the effect of pravastatin therapy on cancer risk and to examine whether the effect varies according to age by performing a detailed meta-analysis and meta-regression analysis of randomized controlled trials.We (...) performed a comprehensive literature search for relevant studies published before February 2006. Before analysis, the selected studies were evaluated for publication bias and heterogeneity. Pooled relative risk estimates with 95% confidence intervals (CIs) were calculated using fixed-and random-effects models. Meta-regression analysis was performed to examine the impact of age on the study estimates of the relative risk of cancer due to pravastatin therapy.Twelve trials that investigated the use

2007 Canadian Medical Association Journal PubMed abstract

18. Does pravastatin promote cancer in elderly patients: a meta-analysis

Does pravastatin promote cancer in elderly patients: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 DARE.

19. [Clinical protocol. Pravastatin for the prevention of the destruction of the nutritional status of hemodialysis patients exhibiting chronic inflammation]. (Abstract)

[Clinical protocol. Pravastatin for the prevention of the destruction of the nutritional status of hemodialysis patients exhibiting chronic inflammation]. 16895670 2006 10 04 2013 11 21 1769-7255 1 1 2005 Mar Nephrologie & therapeutique Nephrol. Ther. [Clinical protocol. Pravastatin for the prevention of the destruction of the nutritional status of hemodialysis patients exhibiting chronic inflammation]. 75-6 Nardi Hervé H fre Letter Multicenter Study Randomized Controlled Trial Etude PREDEN (...) . Prévention par la pravastatine de la dégradation de l'état nutritionnel des patients hémodialysés présentant un état inflammatoire chronique. 2005 04 01 France Nephrol Ther 101248950 1769-7255 0 Hydroxymethylglutaryl-CoA Reductase Inhibitors 0 Placebos 9007-41-4 C-Reactive Protein KXO2KT9N0G Pravastatin IM C-Reactive Protein analysis Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use Inflammation etiology prevention & control Malnutrition etiology prevention & control Placebos

2006 Nephrologie & therapeutique Controlled trial quality: uncertain

20. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. (Abstract)

Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Evidence-based treatment for hypercholesterolaemia in Japan has been hindered by the lack of direct evidence in this population. Our aim was to assess whether evidence for treatment with statins derived from western populations can be extrapolated to the Japanese population.In this prospective, randomised, open-labelled, blinded study, patients (...) with hypercholesterolaemia (total cholesterol 5.69-6.98 mmol/L) and no history of coronary heart disease or stroke were randomly assigned diet or diet plus 10-20 mg pravastatin daily. The primary endpoint was the first occurrence of coronary heart disease. Statistical analyses were done by intention to treat. This trial is registered at ClinicalTrials.gov, number NCT00211705.3966 patients were randomly assigned to the diet group and 3866 to the diet plus pravastatin group. Mean follow-up was 5.3 years. At the end

2006 Lancet Controlled trial quality: predicted high